Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Frédérique PENAULT-LLORCA is currently professor of pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin. She serves as vice-president of the UNICANCER group and chairs of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, with her main areas of expertise being female cancers. She co-chairs the French breast cancer guidelines of Nice-St Paul. Frédérique PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, lung, digestive tract, prostate and thyroid cancer in relation to response to targeted therapies and immunotherapies. Frédérique PENAULT-LLORCA has participated to more than 469 peer-reviewed publications and several books on female cancers and pathologic testing methods and issues.

Prof. Frédérique PENAULT-LLORCA has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Daiichi Sankyo, Roche, Seagreen, Novartis, Lilly, Gilead, Pfizer, MSD, BMS, Janssen